In the News: Lipokinetix and Hepatitis
In the News: Lipokinetix and Hepatitis
The Food and Drug Administration (FDA) is urging consumers to discontinue use of the dietary supplement Lipokinetix®, which has been associated with multiple reports of hepatitis and hepatic failure.
Marketed by Syntrax Innovations, Inc. for weight loss, Lipokinetix contains phenylpropanolamine (norephedrine), caffeine, yohimbine (Pausinystalia johimbe), diiodothyronine, and sodium usniate. The injuries reported to the FDA occurred in persons ages 20-32 years; liver injury developed after 2-12 weeks of Lipokinetix use. No other apparent causes of liver injury were identified in these reports.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.